-+ 0.00%
-+ 0.00%
-+ 0.00%

BTIG Reiterates Buy on Aldeyra Therapeutics, Maintains $9 Price Target

Benzinga·09/29/2026 16:30:44
Listen to the news
BTIG analyst Thomas Shrader reiterates Aldeyra Therapeutics (NASDAQ:ALDX) with a Buy and maintains $9 price target.